DealsAug 5, 2026, 06:51 AM
Eton Pharma Licenses US Rights for ASN-001, a Late-Stage Drug
AI Summary
Eton Pharmaceuticals announced it has licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage product candidate for proliferating superficial infantile hemangiomas. This acquisition positions Eton to address the full spectrum of infantile hemangioma treatment, complementing its existing product HEMANGEOL. The company plans to submit a New Drug Application (NDA) in the second half of 2027, with potential approval and launch in 2028, targeting an estimated 20,000 to 30,000 patients annually.
Key Highlights
- Eton Pharmaceuticals licensed U.S. rights to rare disease product candidate ASN-001 from Auson Pharmaceuticals.
- ASN-001 targets moderate infantile hemangiomas, complementing Eton's HEMANGEOL.
- Phase II/III trial showed 56% (BID) and 42% (TID) elimination/near-elimination rates vs. 15% for placebo.
- NDA submission for ASN-001 is anticipated in 2H 2027, with potential approval and launch in 2028.
- Estimated 20,000 to 30,000 patients annually could be candidates for ASN-001.
- ASN-001 has patent protection through 2044, with an additional patent application pending.
Price Impact
More from ETON